PMC:7283670 / 84354-84826 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T282","span":{"begin":64,"end":69},"obj":"Body_part"},{"id":"T283","span":{"begin":298,"end":302},"obj":"Body_part"},{"id":"T284","span":{"begin":365,"end":370},"obj":"Body_part"}],"attributes":[{"id":"A282","pred":"fma_id","subj":"T282","obj":"http://purl.org/sig/ont/fma/fma68877"},{"id":"A283","pred":"fma_id","subj":"T283","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A284","pred":"fma_id","subj":"T284","obj":"http://purl.org/sig/ont/fma/fma9670"}],"text":"Primary (28 days):\nDisappear time of ground‐glass shadow in the lungs\nSecondary:\nRate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days)"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T177","span":{"begin":365,"end":370},"obj":"Body_part"}],"attributes":[{"id":"A177","pred":"uberon_id","subj":"T177","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"Primary (28 days):\nDisappear time of ground‐glass shadow in the lungs\nSecondary:\nRate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T694","span":{"begin":64,"end":69},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T695","span":{"begin":282,"end":285},"obj":"http://purl.obolibrary.org/obo/PR_000001004"},{"id":"T696","span":{"begin":291,"end":294},"obj":"http://purl.obolibrary.org/obo/CLO_0053438"},{"id":"T697","span":{"begin":296,"end":302},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T698","span":{"begin":327,"end":331},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T699","span":{"begin":365,"end":370},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T700","span":{"begin":365,"end":370},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T701","span":{"begin":396,"end":400},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"}],"text":"Primary (28 days):\nDisappear time of ground‐glass shadow in the lungs\nSecondary:\nRate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T331","span":{"begin":241,"end":253},"obj":"Chemical"},{"id":"T332","span":{"begin":249,"end":253},"obj":"Chemical"},{"id":"T333","span":{"begin":371,"end":377},"obj":"Chemical"},{"id":"T334","span":{"begin":457,"end":462},"obj":"Chemical"}],"attributes":[{"id":"A331","pred":"chebi_id","subj":"T331","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A332","pred":"chebi_id","subj":"T332","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A333","pred":"chebi_id","subj":"T333","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A334","pred":"chebi_id","subj":"T334","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"}],"text":"Primary (28 days):\nDisappear time of ground‐glass shadow in the lungs\nSecondary:\nRate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days)"}

{"project":"LitCovid-sentences","denotations":[{"id":"T733","span":{"begin":19,"end":69},"obj":"Sentence"},{"id":"T734","span":{"begin":70,"end":80},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Primary (28 days):\nDisappear time of ground‐glass shadow in the lungs\nSecondary:\nRate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days)"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T249","span":{"begin":170,"end":175},"obj":"Phenotype"}],"attributes":[{"id":"A249","pred":"hp_id","subj":"T249","obj":"http://purl.obolibrary.org/obo/HP_0001945"}],"text":"Primary (28 days):\nDisappear time of ground‐glass shadow in the lungs\nSecondary:\nRate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days)"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1859","span":{"begin":282,"end":285},"obj":"Gene"},{"id":"1860","span":{"begin":291,"end":294},"obj":"Gene"}],"attributes":[{"id":"A1859","pred":"tao:has_database_id","subj":"1859","obj":"Gene:920"},{"id":"A1860","pred":"tao:has_database_id","subj":"1860","obj":"Gene:925"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Primary (28 days):\nDisappear time of ground‐glass shadow in the lungs\nSecondary:\nRate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days)"}